(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2(Date:9/3/2008)...G, Md., Sept. 3 /- Panacea Pharmaceut...atent Number 7,413,737 covering,antibodies against...AH), a,proprietary human cancer biomarker and ther... collaboration with the Massachusetts Institute of...wide rights to this patent,for development of huma...
(Date:9/3/2008)... Trial Reconfirms Strong Evidence Pycnogenol(R) Lo...ffect on Joints Following Cessation .... 3 /- According to the Center for,Di...on type of arthritis,is on the rise. A new study ...search, reveals Pycnogenol(R), bark extract from t...
(Date:9/2/2008)...ember 3 /-, - This Analysi...e Risk,of Stroke by 34% in Patients With Atrial Fi...eated by Antithrombotic Therapy, The results of a...dy,were presented today at the clinical trial upda...ongress 2008, in Munich, Germany. Previous results...
(Date:9/2/2008)...y Meets Primary Bone Mineral Density and Secondary... Company to Host Conference Call and Webcast Wedn...0 am ET / 5:30 am PT, SAN DIEGO, Sept. 2 /PRNewsw...sdaq: NBIX ) today announced positive safety and ...trial using its proprietary, orally-active,nonpept...
Breaking Medicine Technology:Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 2Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 3Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 4Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 6Reflecting on the social implications of human genetics research past present and future 2780 1Reflecting on the social implications of human genetics research past present and future 2780 2Analysis Highlights Economic Contribution of Hospitals to Communities 16090 1Analysis Highlights Economic Contribution of Hospitals to Communities 16090 2Quest Diagnostics to Release First Quarter 2008 Financial Results and Conduct Quarterly Investor Conference Call 16088 1Quest Diagnostics to Release First Quarter 2008 Financial Results and Conduct Quarterly Investor Conference Call 16088 2VA Announces SGLI and VGLI Premium Reductions 16086 1VA Announces SGLI and VGLI Premium Reductions 16086 2...nistration show potential for,new option to improv...07 /PRNewswire-FirstCall/ -- Millennium,Pharmaceut...sitive,data for VELCADE, the market-leading therap... received at least one prior therapy.,These data i...ous,(SC) administration of VELCADE, a new option u...
...llicular Lymphoma Reported,Today at ASCO Annual Me... GlaxoSmithKline plc,announced today long-term eff...eek course of frontline treatment with the BEXXAR(...31 Tositumomab) in,76 patients with newly diagnose.... This regimen was found to induce durable clinica...
Other Medicine Technology:New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 78-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
Medicine Products:Allergens, Upper Respiratory Disease Profile, Region 5, Greater Ohio Valley (IN, OH, WV, KY, TN)Allergens, Upper Respiratory Disease Profile, Region 2, Mid-Atlantic States (DE, MD, VA, DC, NC)Allergens, Pediatric Inhalants, SouthwestAllergens, Pediatric Foods/Inhalants Profile